"After 72 weeks, nearly 63 percent of those who received semaglutide injections and around 34 percent of those on placebo shots saw their liver condition improve."
"Patients may need a liver transplant, or can die from severe forms of metabolic dysfunction-associated steatohepatitis, highlighting the urgency of effective treatments."
Recent research published in the New England Journal of Medicine indicates that semaglutide, a key ingredient in Wegovy, may effectively treat metabolic dysfunction-associated steatohepatitis (MASH), a liver disease affecting approximately 15 million Americans. A Phase 3 trial with 800 participants revealed that 63% of those receiving semaglutide injections experienced improvements in liver fat and inflammation compared to 34% in the placebo group. This condition is tied to obesity and Type 2 diabetes, making effective treatment crucial to prevent potential liver failure or the need for transplants.
#semaglutide #wegovy #metabolic-dysfunction-associated-steatohepatitis #liver-disease #clinical-trials
Read at www.nytimes.com
Unable to calculate read time
Collection
[
|
...
]